On September 9th, Eli Lilly and Company made a significant announcement: the introduction of its TuneLab platform, which leverages artificial intelligence and machine learning. This innovative platform grants biotech firms access to AI-driven drug discovery models. These models have been meticulously trained on years of research data and incorporate proprietary information, with the company having invested over $1 billion in this endeavor. This move aligns with common practices in the English-speaking business world, where companies often share advanced technological resources to foster industry-wide innovation and collaboration.